Merck’s Keytruda helps lung cancer patients live longer in trial
(Reuters) – Merck & Co’s (MRK.N) blockbuster drug Keytruda helped previously untreated lung cancer patients live longer in a late-stage trial, potentially cementing its position as the dominant player in…